Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMGC Pharmaceuticals Ltd

MGC Pharmaceuticals Ltd

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.415 AUD 0.00(0%)
Last update at 2024-04-29T00:00:00Z
VOLUME
6035
Market Cap
18.42M

Momentum Score

…

MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. In addition, the company provides Irnican that is in preclinical phase for the tetrahydrocannabinol, as well as offers ArtemiC and non-pharma products. Further, it offers consulting services, including clinical research services. MGC Pharmaceuticals Limited was founded in 2014 and is based in Subiaco, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.41
Low
0.42
High
52 Week Price Range
0.30
Low
9.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.41
Dividend Yield
-
Revenue TTM
1.32M
Revenue Per Share
0.10
Gross Profit TTM
1.29M
Debt / Equity
-0.08
ROE
-307.40%
Net Debt
0.34M
ROCE
473.48%
Diluted EPS TTM
-3.21

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -21.13M -17.14M -13.53M -18.81M -1.88M
Minority interest 0.31M 0.37M -0.01M -0.01M -0.16M
Net income -20.82M -16.77M -13.97M -19.36M -1.90M
Selling general administrative 12.49M 8.28M 5.73M 6.61M 2.61M
Selling and marketing expenses 0.93M 0.95M 0.58M 0.56M 0.57M
Gross profit 1.45M 1.63M 1.31M 0.13M 0.30M
Reconciled depreciation 0.49M 0.50M 0.49M 0.48M 0.26M
Ebit -15.99M -14.63M -12.49M -9.50M 0.62M
Ebitda -15.50M -14.12M -12.00M -9.02M 0.88M
Depreciation and amortization 0.49M 0.50M 0.49M 0.48M 0.26M
Operating income -15.23M -15.50M -11.94M -11.29M 0.62M
Other operating expenses -20.06M -16.95M -14.74M -16.92M 9.70M
Interest expense 0.34M 0.19M 0.37M 0.14M 0.01M
Tax provision 0.00M 0.00M -0.03M 0.00M 0.03M
Interest income 0.34M 0.00M 0.36M 0.01M 0.20M
Net interest income -0.34M -0.19M -0.36M -0.12M 0.19M
Extraordinary items - - -0.46M -0.60M 2.43M
Income tax expense 0.00M -1.36M -0.03M 1.21M 0.03M
Total revenue 3.39M 4.65M 2.96M 2.03M 0.66M
Total operating expenses 17.15M 15.08M 13.38M 12.55M 9.34M
Cost of revenue 1.94M 3.01M 1.65M 1.90M 0.36M
Total other income expense net -5.10M -3.50M -1.10M -8.66M -2.50M
Discontinued operations - - -0.46M -0.60M 2.43M
Net income from continuing ops -21.13M -17.14M -13.50M -18.81M -1.90M
Net income applicable to common shares -20.82M -16.77M -15.87M -19.36M -8.58M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 9.88M 18.56M 24.24M 7.93M 13.00M
Intangible assets 0.00M 5.38M 7.05M 0.00M 5.03M
Other current assets 0.40M -0.90M 0.83M 0.43M 0.09M
Total liab 18.02M 13.38M 10.41M 4.83M 2.20M
Total stockholder equity -7.51M 5.74M 13.83M 3.11M 10.96M
Other current liab 10.30M 3.67M 4.29M 0.11M 0.37M
Common stock 103.71M 97.44M 77.75M 60.15M 49.13M
Capital stock 103.71M 97.44M 84.51M 60.15M 49.13M
Retained earnings -119.17M -94.76M -76.09M -62.13M -41.46M
Other liab 4.30M 2.38M 2.51M 0.02M 0.02M
Good will - 5.38M 7.05M 7.05M -
Other assets 0.00M 0.16M 0.56M - -
Cash 0.24M 1.79M 5.43M 1.87M 2.35M
Cash and equivalents - - - - 2.35M
Total current liabilities 13.26M 7.71M 6.13M 2.97M 2.18M
Current deferred revenue 0.58M 1.38M -4.28M 0.10M 0.59M
Net debt 0.34M 0.51M 1.24M 0.03M -0.45M
Short term debt 0.19M 0.15M 4.90M 0.05M 0.05M
Short long term debt - 2.10M 4.69M - -
Short long term debt total 0.58M 2.29M 6.67M 1.90M 1.90M
Other stockholder equity 0.21M -5.88M -6.51M 5.08M 4.59M
Property plant equipment 7.45M 9.70M 7.14M 4.02M 1.47M
Total current assets 2.43M 6.46M 9.48M 3.23M 3.72M
Long term investments - 0.16M - 0.67M 2.77M
Net tangible assets -7.40M 6.23M 6.79M 3.11M 5.93M
Net receivables 0.53M 3.35M 2.35M 0.41M 1.14M
Long term debt - - 0.00M 0.00M 0.00M
Inventory 1.26M 2.22M 0.87M 0.40M 0.14M
Accounts payable 2.19M 2.50M 1.22M 2.71M 1.16M
Accumulated other comprehensive income 7.95M 8.94M 7.32M 5.08M 3.29M
Common stock total equity - - - 60.15M 49.13M
Non currrent assets other - 0.16M 0.56M 0.56M 2.77M
Non current assets total 7.45M 12.10M 14.75M 4.70M 9.28M
Capital lease obligations 0.58M 2.29M 1.98M 1.90M -
Long term debt total 0.38M 2.14M 1.77M 1.85M 0.00M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 0.05M -2.44M 0.30M -0.97M -0.95M
Change to liabilities 0.19M 1.63M -0.82M 0.52M 0.63M
Total cashflows from investing activities 0.61M -2.44M -1.49M -0.97M -0.95M
Net borrowings 6.96M -0.26M 5.49M -0.18M -0.18M
Total cash from financing activities 9.31M 9.74M 16.68M 10.65M 0.03M
Net income -20.82M -20.35M -15.87M -19.36M -2.31M
Change in cash -1.65M -3.66M 3.56M -0.48M -7.50M
Begin period cash flow 1.89M 5.43M 1.87M 2.35M 9.86M
End period cash flow 0.24M 1.77M 5.43M 1.87M 2.35M
Total cash from operating activities -11.99M -12.16M -11.99M -9.96M -6.35M
Issuance of capital stock 2.70M 10.76M 12.76M 11.43M 0.04M
Depreciation 0.75M 0.14M 0.49M 0.48M 0.26M
Other cashflows from investing activities 0.80M 1.58M 2.45M -0.01M -0.57M
Dividends paid -0.22M -0.06M 0.06M - -
Change to inventory 0.48M -0.97M -0.47M -0.26M 0.57M
Change to account receivables 1.41M 1.29M -2.22M 0.27M -0.29M
Sale purchase of stock -0.08M -0.76M -1.20M -0.79M -0.01M
Other cashflows from financing activities 7.13M -0.14M 5.12M -0.97M -0.95M
Change to netincome 6.02M 5.94M 6.90M 8.40M 1.05M
Capital expenditures 0.74M 4.02M 3.33M 0.96M 0.36M
Change in working capital 1.88M 0.33M -2.69M 0.01M -2.41M
Stock based compensation 2.66M 0.64M 1.65M 0.85M -
Other non cash items 8.09M 8.05M 3.39M 8.93M 2.05M
Free cash flow -12.72M -16.18M -15.32M -10.92M -6.72M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MXC
MGC Pharmaceuticals Ltd		 -
-%		 0.41 - 14.90 13.91 13.86 7.66 -0.83
AFP
Aft Pharmaceuticals Ltd		 0.05
1.41%		 3.60 29.92 18.18 1.48 4.37 2.05 18.56
VLS
Vita Life Sciences Ltd		 0.09
3.42%		 2.72 13.50 42.73 1.52 2.62 1.19 7.17
LGP
Little Green Pharma Ltd		 0.01
16.67%		 0.07 - 10.00 0.64 0.60 1.25 19.47
MVP
Medical Developments International Ltd		 -
-%		 0.44 40.00 166.67 1.06 0.79 0.57 7.45

Profile*

MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. In addition, the company provides Irnican that is in preclinical phase for the tetrahydrocannabinol, as well as offers ArtemiC and non-pharma products. Further, it offers consulting services, including clinical research services. MGC Pharmaceuticals Limited was founded in 2014 and is based in Subiaco, Australia.

295 Rokeby Road, Subiaco, WA, Australia, 6008

61 8 6555 2950

https://mgcpharma.com.au

Name Title Year Born
Mr. Roby Reuven Zomer Co-Founder, CEO, MD & Exec. Director 1980
Ms. Angela-Marie Graham Group Chief Financial Officer NA
Ms. Yifat Steuer Deputy CEO & COO NA
Mr. Amir Polak Chief Technology Officer NA
Ms. Nicole Ann Godresse Global Chief Sales Officer NA
Ms. Sabina Suljakovic Head of the Quality Assurance Department NA
Dr. Nadya Lisovoder Chief Medical Officer NA
Ms. Sasha Friedman Deputy CEO NA
Yair Tal Chief Information Security Officer NA
Mr. Robert Clements Chief Commercial Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…